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Mutations in the ABCC6 Gene as a Cause of
Generalized Arterial Calcification of Infancy:
Genotypic Overlap with Pseudoxanthoma Elasticum
Qiaoli Li1,9, Jill L. Brodsky2,3,9, Laura K. Conlin4, Bruce Pawel4, Andrew C. Glatz3,5, Rachel I. Gafni6,
Leon Schurgers7, Jouni Uitto1, Hakon Hakonarson3,8, Matthew A. Deardorff3,8 and Michael A. Levine2,3
Generalized arterial calcification of infancy (GACI) is an autosomal recessive disorder characterized by congenital
calcification of large- and medium-sized arteries, associated with early myocardial infarction, heart failure, and
stroke, and premature death. Most cases of GACI are caused by mutations in the ENPP1 gene. We first studied
two siblings with GACI from a non-consanguineous family without mutations in the ENPP1 gene. To search for
disease-causing mutations, we identified genomic regions shared between the two affected siblings but not their
unaffected parents or brother. The ABCC6 gene, which is mutated in pseudoxanthoma elasticum (PXE), resided
within a small region of homozygosity shared by the affected siblings. Sequence analysis of ABCC6 revealed that
the two affected siblings were homozygous for the missense mutation p.R1314W. Subsequently, ABCC6
mutations were identified in five additional GACI families with normal ENPP1 sequences. Genetic mutations in
ABCC6 in patients with PXE are associated with ectopic tissue mineralization in the skin and arterial blood
vessels. Thus, our findings provide additional evidence that the ABCC6 gene product inhibits calcification under
physiologic conditions and confirm a second locus for GACI. In addition, our study emphasizes the potential
utility of shared homozygosity mapping to identify genetic causes of inherited disorders.
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INTRODUCTION
Generalized arterial calcification of infancy (GACI, OMIM#
208000) is an autosomal recessive disorder that is characteri-
zed by calcification of the internal elastic lamina of large- and
medium-sized arteries and stenosis because of fibroprolifera-
tion of the intima of muscular arteries. Radiographs show both
arterial and periarticular soft tissue calcifications. GACI
usually presents with congestive cardiac failure, hypertensive
disease, and/or myocardial ischemia, and the majority of
children die within the first 6 months of life (Maayan et al.,
1984), with only a few case reports of survivors into later
childhood or adulthood (Rutsch et al., 2003; Patel et al., 2004;
Ciana et al., 2006; van der Sluis et al., 2006).
Most, but not all, patients with GACI have recessive
mutations in the ENPP1 gene (OMIM# 173335) located on
chromosome 6q22-q23 (Rutsch et al., 2003), suggesting that
GACI is genetically heterogeneous. ENPP1 encodes the ecto-
nucleotide pyrophosphatase phosphodiesterase 1 (ENPP1, EC
3.6.1.9, EC 3.1.4.1) enzyme that regulates soft tissue calcifi-
cation and bone mineralization by generating inorganic
pyrophosphate (PPi), an essential inhibitor of hydroxyapatite
deposition. Hence, GACI patients with deficiency of ENPP1
are unable to synthesize sufficient PPi to inhibit ectopic
mineralization and are, therefore, prone to arterial calcifica-
tion. In addition to a deficiency of PPi, recent studies indicate
that some children with GACI due to ENPP1 mutations
develop hypophosphatemia after the first year of life (Rutsch
et al., 2008). Hypophosphatemia is assumed to be mediated
by elevated plasma levels of the phosphatonin FGF23, which
inhibits expression and internalization of the renal sodium-
phosphate cotransporters SLC34A1 and SLC34A3 and inhibits
synthesis of 1.25-dihydroxyvitamin D. In patients with GACI,
hypophosphatemia appears to ameliorate soft tissue calcifi-
cation (Rutsch et al., 2008). Remarkably, other patients with
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ENPP1 mutations develop hypophosphatemic rickets rather
than GACI, a paradox that at present lacks a biochemical
explanation (Rutsch et al., 2008; Levy-Litan et al., 2010;
Lorenz-Depiereux et al., 2010).
Sequence analyses of ENPP1 have failed to disclose disease-
causing mutations in approximately 25% of subjects with
GACI (Le Boulanger et al., 2010), and linkage analyses have
pointed to other chromosomal regions where other pathogenic
genes may be located (Ruf et al., 2005). Recently, Nitschke
et al. (2012) described a cohort of patients with GACI with
mutations in ABCC6, which has previously been implicated
in pseudoxanthoma elasticum (PXE; Uitto et al., 2010) and a
variant of GACI (Le Boulanger et al., 2010), suggesting
that this gene has a causative role in this disorder. Before
these publications, we investigated two siblings born to non-
consanguineous parents with severe GACI and normal
sequences for ENPP1 (Li et al., 2012a). We performed a
genome-wide search for a genetic defect underlying GACI and
searched for replication of the best candidates in a larger
independent cohort of children with GACI. Here we describe
additional patients with mutations in the ABCC6 gene as the
second locus for GACI, emphasizing the genotypic overlap
between GACI and PXE.
RESULTS
Clinical findings
A total of seven patients in six families with clinical manifesta-
tions consistent with GACI were examined; these families are
referred to as Families A–F. The nuclear pedigrees of these
families are shown in Figure 1, and the diagnostic clinical
characteristics are shown in Figure 2 and are detailed in
Supplementary Material online.
Identification of ABCC6 as a candidate gene
We initially focused on Family A with two affected siblings
with characteristic features of GACI (Figure 2a). Sequencing of
ENPP1 as one of the candidate genes for mutations (Table 1),
which is known to cause GACI, did not reveal the presence
of pathogenic mutations. To facilitate the identification of
the molecular basis of GACI in this family, we performed
genome-wide (610 K) single-nucleotide polymorphism array
analysis on all individuals. We analyzed the data from the
three siblings and the parents to phase informative single-
nucleotide polymorphism markers and determine shared
haplotype segments between the affected siblings that were
not also shared with the unaffected sibling. As expected, this
analysis confirmed the exclusion of ENPP1 as a candidate
gene, as well as the MGP and ADIPOQ genes, each consi-
dered as candidates based on known association to miner-
alization (Table 1). Further analysis of the genotypes within
the region containing the ABCC6 gene revealed that the shared
haplotypes between the affected siblings reside in a relatively
small, 799 kb region of homozygosity, thus identifying ABCC6
as the primary candidate gene for mutations in this family.
We subsequently used Sanger sequencing to assess the
ABCC6 gene for mutations in affected members of this family
and other unrelated individuals in additional families with
GACI.
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Figure 1. Nuclear pedigrees of Families A–F with generalized arterial calcification of infancy. The mutations discovered in the ABCC6 gene in the individual
family members are indicated below each individual: þ /þ , homozygous for the wild-type allele; þ / , heterozygous carrier;  / , mutations in both alleles.
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Mutations in the ABCC6 gene underlie GACI
We used PCR to amplify and directly sequence all 31 exons
and the flanking intronic sequences of the ABCC6 gene in
patients with GACI with normal ENPP1 sequences, as well
as their unaffected family members. Affected members of
Family A (patients 1 and 2), who shared a 799-kb region
of homozygosity on chromosome 16, were found to have
homozygous missense mutations (c.3940C4T, p.R1314W) in
exon 28 of ABCC6 (Figure 3). This missense mutation replaces
a conserved arginine residue with tryptophan in the second
nucleotide-binding fold of ABCC6. The proband in Family B
(patient 3) was found to have compound heterozygous
mutations (c.2787þ 1G4T and c.3736-1G4A) in introns 21
and 26 of ABCC6. The proband in Family D (patient 5) had
compound heterozygous mutations c.346-6G4A and
p.R1141X in intron 3 and exon 24 of ABCC6. In Family F,
the proband (patient 7) was found to carry compound
heterozygous mutations consisting of a large deletion (g.del
23–29) and a missense mutation (p.R760W). The arginine-
to-tryptophan substitution affects the first nucleotide-binding
fold of ABCC6 protein. Only one ABCC6 mutation has been
identified for the proband of Family C (patient 4; p.R391G)
and the proband of Family E (patient 6; c.3692insTT). The
p.R391G mutation resides in the fourth intracellular loop
corresponding to the second transmembrane domain of
ABCC6 protein, whereas the c.3692insTT mutation causes a
frameshift and predicts truncation of the protein as a result of a
premature termination codon 125 bp downstream of the
mutation and likely leads to nonsense-mediated mRNA decay
(Table 2). Multiplex ligation-dependent probe amplification
failed to identify additional deletion mutations in Families C
and E. All the identified mutations, with the exception of the
mutation c.3692insTT, have previously been reported in
subjects with PXE as biallelic mutations, and are predicted
to result in reduction or loss of ABCC6 activity (Pfendner et al.,
2007; Uitto et al., 2010).
a
d e f
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Figure 2. Ultrasound and histopathologic features in individuals with generalized arterial calcification of infancy (GACI). (a) Ultrasound of patient 1 in
Family A (II-3) reveals, in lateral sagittal view of head, calcifications along the cores of lenticulostriate vessels (arrow). (b–d) Histopathology of patient 3 in
Family B (II-1) shows calcification of mesenteric artery (b), abdominal artery (c), and left renal artery (d); hematoxylin-eosin stain, original magnifications  150.
(e) Patient 6 in Family E (II-1) demonstrated by ultrasound imaging portions of the proximal external carotid artery with thickened walls and irregular,
speckled calcification (arrows). (f) Patient 7 in Family F (II-3), prenatal ultrasound of aortic bifurcation demonstrates extensive calcification (arrows).
Table 1. Candidate genes for GACI identified by shared homozygosity analysis in Family A with two affected patients
with an unaffected sibling
Gene Reason assessed
Excluded from
affected siblings
Excluded using affected
and unaffected Comments on haplotype analysis
ENPP1 Common cause of GACI No Yes Same haplotypes in all three children
MGP Anti-mineralization factor Yes Yes Different in affected siblings
ADIPOQ Adiponectin involved in mineralization Yes Yes Different in affected siblings
ADIPOR1 Adiponectin, type 1 receptor No No Possible candidate gene
ABCC6 Common cause of PXE No No All SNPs over a region of homozygosity
Abbreviations: GACI, generalized arterial calcification of infancy; PXE, pseudoxanthoma elasticum; SNP, single-nucleotide polymorphism.
Q Li et al.
ABCC6 Mutations in GACI
660 Journal of Investigative Dermatology (2014), Volume 134
Biochemical findings
Serum levels of calcium, phosphorus, and alkaline phospha-
tase were normal in all subjects (data not shown). In addition,
because circulating FGF23 is elevated in patients with GACI
due to ENPP1 mutations, we measured plasma levels of
FGF23 using an immunoassay that detects both the intact
form and carboxy-terminal fragments of FGF23 protein. We
found that circulating levels of FGF23 were normal in all
affected subjects from whom serum could be obtained
(Table 2).
Immunofluorescence findings in arterial blood vessels
To further characterize the consequences of the ABCC6
mutations, we performed histopathologic examination of
arteries in patients with GACI, investigating the activation
status of matrix gla protein (MGP), a powerful, local
anti-mineralization factor when activated by g-glutamyl
carboxylation and which has been implicated in the patho-
mechanism of PXE (Berkner, 2008; Uitto et al., 2010). We also
examined for the presence of fetuin-A, a systemic anti-
mineralization factor on the lesional area of mineralized
blood vessels (Brylka and Jahnen-Dechent, 2013). Histopatho-
logy of the affected vessels revealed extensive mineralization.
Because MGP has been shown to participate in the arterial
mineralization processes, the presence of both carboxylated
(cMGP, active) and uncarboxylated (ucMGP, inactive) forms
of this protein was investigated by immunofluorescence with
conformation-specific mAbs (Schurgers et al., 2005). Although
the active form (cMGP) was detectable in association with the
mineral deposits (Figure 4, frame A), a similar, but stronger
staining pattern was noted with the antibody-recognizing
ucMGP (Figure 4, frame B), suggesting that MGP was
predominantly in the inactive form. Immunostaining with an
antibody-recognizing fetuin-A revealed co-localization of the
protein with the mineral deposits (Figure 4, frame C). The
controls without the primary antibody were negative (Figure 4,
frames D–F).
DISCUSSION
In this study, we used a strategy of shared haplotype mapping
to identify potential candidate genes for GACI in a family with
two affected siblings and one unaffected sibling, confirmed by
Sanger sequencing. This mapping led to the identification of
ABCC6, which has been previously shown to be mutated in
patients with PXE (Pfendner et al., 2007; Uitto et al., 2010) or
associated in heterozygous state with premature coronary
artery disease (Trip et al., 2002; Ko¨blo¨s et al., 2010), as the
candidate gene. These studies indicate the usefulness of both
shared haplotype and homozygosity analysis for identification
of genetic causes of rare inherited disorders in patients even
from apparently non-consanguineous families. Our results
confirm the successful use of individuals from outbred
populations in homozygosity mapping (Hildebrandt et al.,
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Figure 3. Mutation analysis of the ABCC6 gene in Family A with generalized
arterial calcification of infancy (GACI). Sequencing of the ABCC6 gene
in patients 1 and 2 (II-3 and II-4 in Figure 1) revealed a homozygous
nucleotide T substitution (b) replacing nucleotide C in the control DNA (a).
This mutation results in substitution of arginine (R) by tryptophan (W) at
amino-acid position 1314. The arginine residue is well conserved through
evolution (c).
Table 2. Molecular and biochemical features of GACI
patients
Patient Family Age Mutation 1 Mutation 2
Mutation
type
Plasma
[FGF23],
RUml1 1
1 A 3 Yrs p.R1314W p.R1314W MS/MS 59
2 A 6 Yrs p.R1314W p.R1314W MS/MS 97
3 B 1 Mo c.2787þ1G4T c.3736-1G4A SS/SS NT2
4 C 5 Yrs p.R391G ND MS/ND 83
5 D 1 Mo p.R1141* c.346-6G4A NS/SS3 NT
6 E 1 Mo c.3692 insTT ND FS/ND 374
7 F 1 Mo p.R760W del23-29 MS/del 1,430
Abbreviations: FS, frame shift; GACI, generalized arterial calcification
of infancy; Mo, month; MS, missense; ND, not detected; NS, nonsense;
NT, not tested; SS, splice site; Yrs, years.
1FGF23 normal range is o230 RU ml1 for ages 3 mo to 17 yrs. Values
greater than 900 RU ml 1 are present in infants.
2NT as serum sample was not available.
3The effects of the c.346-6G4A mutation on splicing have not been
experimentally confirmed.
Q Li et al.
ABCC6 Mutations in GACI
www.jidonline.org 661
2009), which together with rapid next generation sequencing,
should greatly accelerate gene discovery.
We subsequently used Sanger sequencing to confirm the
association between ABCC6 and GACI in five additional
unrelated families where the clinically affected subjects had
normal ENPP1 gene sequences. We identified mutations in
both alleles of ABCC6 in three subjects, but we found only a
single mutant allele in two patients with GACI. Our results are
similar to those noted in other studies in which mutations in
both ABCC6 alleles were disclosed in only B80% of patients
with PXE (Pfendner et al., 2007; Uitto et al., 2010). Because
GACI, similar to PXE, is an autosomal recessive disease, it is
likely that individuals with a detectable mutation in only one
allele harbor a second mutation in the other ABCC6 allele
in trans. In this context, it should be noted that the mutation
detection strategy we used to analyze the ABCC6 gene
employs PCR amplification of all exons and flanking intronic
sequences, combined with multiplex ligation-dependent
probe amplification. This combined approach should detect
most point mutations, insertion/deletion mutations, and copy
number variants, but would not detect small mutations in the
promoter region or imbedded in the introns of ABCC6 that
might affect transcription or splicing. An alternate, less likely
possibility is that the affected individuals in Families C and E
demonstrate digenic inheritance because of one mutation in
the ABCC6 gene and a second heterozygous mutation in
another, genetically distinct, yet functionally overlapping gene
involved in ectopic tissue mineralization. This possibility is
raised in light of our recent demonstration that heterozygosity
for one mutation in the ABCC6 gene and one mutation in the
GGCX gene can result in PXE-like cutaneous findings (Li et al.,
2009a).
Our molecular results confirm and extend previous studies
that have indicated a significant overlap between the clinical
features of PXE and GACI (Nitschke and Rutsch, 2012). PXE
predominantly affects the elastic tissues of the skin, eyes, and
cardiovascular system (Neldner, 1988). In the skin, histopatho-
logy demonstrates accumulation of pleiomorphic elastic struc-
tures in the mid- and upper reticular dermis with profound,
progressive mineralization. The eye manifestations charac-
teristically consist of angioid streaks because of mineralization
of an elastin-rich Bruch’s membrane behind the pigmented
retina (Georgalas et al., 2009). Mineralization of this mem-
brane results in blood vessel rupture and subsequent neovas-
cularization, leading to loss of visual acuity and occasionally
to blindness. The cardiovascular manifestations include
arterial calcification resulting in intermittent claudication,
decreased peripheral pulses, hypertension, hemorrhage, and
early myocardial infarcts. A recent report described two
siblings with identical ABCC6 gene mutations that led to
classical PXE in the older brother and a phenotype similar
to GACI in the younger brother (Le Boulanger et al., 2010).
The authors demonstrated that MGP and fetuin-A, involved in
the mineralization process in PXE, were also expressed in the
affected younger sibling with GACI. These proteins act physio-
logically as local and systemic inhibitors of mineralization.
In addition, a patient with GACI due to homozygous mis-
sense mutation in the ENPP1 gene has recently been reported
to have PXE-like cutaneous manifestations consisting of
yellowish papules coalescing into plaques of inelastic skin
(Li et al., 2012b). Skin histopathology of this patient demon-
strated accumulation of pleiomorphic elastotic structures
with progressive mineralization, a diagnostic feature of PXE.
Hence, GACI may be an atypical and severe end of the
vascular phenotype spectrum of PXE. A comparison of clinical
features of PXE and GACI is provided in Table 3. It should
be noted that all the ABCC6 mutations discovered in this study
in patients with GACI, with the exception of a mutation
c.3692ins TT, have been previously reported in patients with
PXE (Pfendner et al., 2007; Li et al., 2009b). The reasons for
the development of such divergent phenotypes as a result of
the same mutation in ABCC6 remain unclear. One could
postulate, however, that genetic modifier genes or epigenetic
factors profoundly alter the phenotypic expression of the
ABCC6 mutations. This notion is supported by recent mouse
studies indicating that a non-synonymous single-nucleotide
polymorphism in the Abcc6 gene, which results in aberrant
mRNA splicing, can result in highly different degrees of
cMGP ucMGP Fetuin-A
– Antibody
+ Antibody
a b c
d e f
Figure 4. Immunofluorescence of the presence of carboxylated (active, cMGP) and uncarboxylated (inactive, ucMGP) forms of matrix gla protein (MGP)
and fetuin-A in patient 3 in Family B (II-1). Immunofluorescence with antibodies recognizing carboxylated (a) and uncarboxylated (b) forms of MGP and
fetuin-A (c). Frames (d–f) represent the corresponding negative controls in which the primary antibodies were omitted.
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mineralization in four inbred mouse strains (Berndt et al.,
2013). Finally, diet, lifestyle variables, and environmental
factors can modify the phenotypic presentations of patients
with PXE, possibly extending to GACI (Uitto et al., 2013).
The basis for the ectopic mineralization in GACI is only
partially understood. Loss-of-function mutations in ENPP1
result in decreased extracellular levels of PPi, an inhibitor
of tissue mineralization. As a result, ectopic deposition of
hydroxyapatite occurs in large- and medium-sized arteries
leading to intimal proliferation, arterial stenosis, and visceral
ischemia. Recently, biallelic loss of function mutations in
ENPP1 have also been identified as a cause of autosomal
recessive hypophosphatemic rickets (Levy-Litan et al., 2010;
Lorenz-Depiereux et al., 2010; Saito et al., 2011; Mehta et al.,
2012). As in other forms of hypophosphatemic rickets, serum
levels of the phosphatonin FGF23 are elevated in rickets
patients with ENPP1 mutations. Hence, we sought to deter-
mine whether loss of ABCC6 might also be associated with
elevated serum concentrations of FGF23. Using an immuno-
assay, we found that serum concentrations of FGF23 were
essentially normal in all affected patients that we assessed.
Thus, it is unlikely that FGF23 has a significant role in the
development of intra-arterial calcification in patients with
GACI.
The mechanism for vascular and soft tissue calcification
in patients with GACI or PXE due to mutations in ABCC6
is unknown (Uitto et al., 2013). The mineral deposits in the
affected tissues of patients with PXE have been shown by
Alizarin Red and von Kossa staining to consist of calcium and
phosphate, and this composition has been confirmed by
energy dispersive X-ray analysis (Kavukcuoglu et al., 2012).
ABCC6 encodes a putative transmembrane transporter
protein, ABCC6, expressed primarily in the baso-lateral
surface of hepatocytes, and previously shown by in vitro
studies to serve as an efflux pump that transports anionic
small-molecular-weight conjugates (Ilias et al., 2002). Interes-
tingly, in vitro, ABCC6 does not transport calcium or
phosphate.
In conclusion, our findings confirm that loss of function
mutations in the ABCC6 gene provide the second genetic basis
for GACI. In addition to ABCC6 and ENPP1, a number of addi-
tional genes can harbor mutations causing heritable diseases
manifesting with ectopic mineralization of the skin and/or
vascular tissues due to mutations in different genes. These
include familial tumoral calcinosis, the normophosphatemic
type being because of mutations in the SAMD9 gene, and the
hyperphosphatemic types because of mutations in FGF23,
GALNT3, and KL genes (Sprecher, 2010). In addition, CD73
deficiency due to mutations in the NT5E gene manifests with
vascular mineralization similar, but distinct from that in PXE
(Markello et al., 2011). At the same time, a number of different
gene products, such as MGP, a-fetuin, and osteopontin, can
serve as powerful anti-mineralization factors. Thus, there is an
intricate network of factors, which either promote or
antagonize mineralization processes, and a delicate balance
between these factors is required under normal physio-
logic conditions to maintain tissue homeostasis and prevent
ectopic mineralization (Rutsch et al., 2011; Li and Uitto,
2013). Collectively, these observations underscore the role of
aberrant expression of such regulatory factors in ectopic
mineralization in humans, providing potential opportunities
for pharmacologic intervention to prevent the development
and progression of these disorders.
MATERIALS AND METHODS
Patients
We studied seven affected individuals from six unrelated families with
clinical features of GACI and normal sequences of the ENPP1 gene
(Figure 1). In all patients, the serum levels of calcium, phosphorus,
alkaline phosphatase, and vitamin D metabolites were normal. The
clinical details of these patients are presented in the Supplementary
Material online.
All patients were enrolled with written informed consent or assent
into an institutional review board-approved study at either the
Children’s Hospital of Philadelphia or the National Institutes of
Health. All studies adhered to the Declaration of Helsinki Principles.
Genome-wide arrays and analyses
DNA samples from Family A were analyzed using Illumina HapMap
Quad610 arrays per manufacturer’s protocol (Illumina, San Diego,
CA), and copy number analysis was performed as described pre-
viously (Shaikh et al., 2009; Conlin et al., 2010). The Homozygosity/
LOH Detector v.1.0.3 Auto-Bookmark plug-in within Illumina
Beadstudio 3.1.3 Genotyping Module 3.3.4 (Illumina, San Diego,
CA) was used for detection of regions of homozygosity. We excluded
the X chromosome from our homozygosity analyses because the male
and female siblings were similarly affected.
Shared haplotypes were determined using parental genotypes to
phase parental alleles for each of the three siblings in Family A.
Subsequently, inconsistent and uninformative genotypes were
removed from the analysis and regions were identified where both
maternal and paternal haplotypes were shared among the affected
siblings but not with the unaffected sibling. Candidate genes were
assessed regarding their exclusion or inclusion from approximate
shared regions (Table 1).
Mutation analysis in the ABCC6 and ENPP1 genes
Genomic DNA was isolated from peripheral blood (QIAamp Blood
Maxi kit; Qiagen, Valencia, CA). PCR was performed using Taq
polymerase (Qiagen) according to the manufacturers’ instructions.
The entire coding region and intron/exon boundaries of the ABCC6
Table 3. Genotypic and phenotypic overlaps of PXE
and GACI
PXE GACI
Vascular mineralization Vascular mineralization
Skin and eye findings Rare skin findings
Late onset Pre- and perinatal diagnosis
Mostly normal life span Demise usually o6 months
ABCC64ENPP1 ENPP14ABCC6
Abbreviations: GACI, generalized arterial calcification of infancy; PXE,
pseudoxanthoma elasticum.
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gene were amplified using PCR primers as described previously
(Pfendner et al., 2007). For the detection of the genomic deletion of
exons 23–29, the primers previously described (Le Saux et al., 2001)
were used. The PCR products were analyzed with direct sequencing
using an Applied Biosystems 3730 Sequencer (Applied Biosystems,
Foster City, CA). The þ 1 in the ABCC6 gene corresponds to the A
nucleotide in the ATG translation initiation codon (GenBank
accession no. AF076622). We subjected DNA from patients in
whom only a single ABCC6 mutation was identified to direct sequen-
cing analysis by multiplex ligation-dependent probe amplification
(SALSA MLPA P092 ABCC6 probemix, MRC-Holland, Amsterdam,
the Netherlands) according to the manufacturer’s recommendations.
Sequencing of the ENPP1 gene was performed as described
previously (Nitschke et al., 2012).
Immunofluorescence
Immunofluorescence of the human arterial sections was performed on
tissues embedded in paraffin. Sections were stained with moAb-
cMGP (4.5 mg ml 1; mAb toward the carboxylated forms of human
MGP), moAb-ucMGP (4.5 mg ml 1; mAb toward the uncarboxylated
forms of human MGP; Schurgers et al., 2005), and goat anti-human
fetuin-A (10mg ml 1; R&D Systems, Minneapolis, MN), respectively.
The secondary antibody, Alexa Fluor 488 goat anti-mouse IgG (1:800;
Invitrogen, Carlsbad, CA) or Alexa Fluor 488 donkey anti-goat IgG
(1:800) (Invitrogen), was applied. Controls for the immunoreactions
were performed by incubating the sections with blocking buffer
instead of the primary antibody.
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